Dr. med. Michael Sulz
M14-675
01.01.2019A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis
Klinische Forschung - 01.01.2019 - 01.08.2020
Abgeschlossen
Projektleitung: Sulz Michael
Mitarbeiter/innen: Brand Stephan, Krieger-Grübel Claudia, Smolders Jolijn
I6T-MC-AMAM
01.01.2019A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease
Klinische Forschung - 01.01.2019 - 01.12.2022
Automatisch geschlossen
Projektleitung: Brand Stephan
Mitarbeiter/innen: Sulz Michael, Smolders Jolijn, Krieger-Grübel Claudia
I6T-MC-AMAN
01.01.2018A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 1
Klinische Forschung - 01.01.2018 - 01.02.2021
Abgeschlossen
Projektleitung: Brand Stephan
Mitarbeiter/innen: Krieger-Grübel Claudia, Sulz Michael, Smolders Jolijn
I6T-MC-AMBG
01.01.2018A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2
Klinische Forschung - 01.01.2018 - 01.06.2021
Automatisch geschlossen
Projektleitung: Brand Stephan
Mitarbeiter/innen: Sulz Michael, Krieger-Grübel Claudia, Smolders Jolijn
ACRE
01.01.2018A MULTICENTER, MULTI-NATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE IIA STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF AN ANTHOCYANIN RICH EXTRACT (ACRE) IN PATIENTS WITH ULCERATIVE COLITIS.
Klinische Forschung - 01.01.2018 - 01.07.2021
Abgeschlossen
Projektleitung: Brand Stephan
Mitarbeiter/innen: Stillhard Roman, Sulz Michael, Krieger-Grübel Claudia, Smolders Jolijn
GA29145
28.08.2017AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144
Klinische Forschung - 28.08.2017 - 28.08.2021
Automatisch geschlossen
Projektleitung: Borovicka Jan
Mitarbeiter/innen: Dora Barbara, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael
GA29144/Bergamot
01.08.2017A PHASE III, RANDOMIZED, DOUBLEBLIND, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
Klinische Forschung - 01.08.2017 - 01.08.2021
Automatisch geschlossen
Projektleitung: Borovicka Jan, Brand Stephan
Mitarbeiter/innen: Dora Barbara, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael
Amiselimod
01.06.2017A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study of Amiselimod (MT-1303) in the Induction and Maintenance of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis
Klinische Forschung - 01.06.2017 - 27.09.2022
Automatisch geschlossen
Mitarbeiter/innen: Knellwolf Christina, Dora Barbara, Krieger-Grübel Claudia, Sulz Michael
M14-533
01.01.2017A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis
Klinische Forschung - 01.01.2017 - 01.12.2022
Automatisch geschlossen
Projektleitung: Sulz Michael
Mitarbeiter/innen: Smolders Jolijn, Brand Stephan
Mongersen GED-0301
01.12.2016A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease.
Klinische Forschung - 01.12.2016 - 01.12.2018
Abgeschlossen
Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael
PCG-4/UCR
01.12.2016Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 48-weeks treatment with gastroresistant phosphatidylcholine (LT-02) versus placebo versus mesalamine for maintenance of remission in...
Klinische Forschung - 01.12.2016 - 01.12.2018
Abgeschlossen
Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael
Abbvie M14-234
01.12.2016A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Klinische Forschung - 01.12.2016 - 01.12.2018
Automatisch geschlossen
Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael
Entyvio PASS Study
28.07.2016Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s Disease. This is a prospective, observational, multi-...
Klinische Forschung - 28.07.2016 - 28.06.2022
Automatisch geschlossen
Projektleitung: Brand Stephan
Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia
PCG-2/UCA
01.03.2016Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 12-weeks add-on treatment with LT-02 (gastro-resistant phosphatidylcholine granules) vs. placebo in patients with ulcerative colitis...
Klinische Forschung - 01.03.2016 - 31.12.2017
Abgebrochen
Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia
GA289103/Gardenia
28.06.2015GA29103: PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS
Klinische Forschung - 28.06.2015 - 28.06.2020
Automatisch geschlossen
Projektleitung: Borovicka Jan
Mitarbeiter/innen: Dora Barbara, Frei Remus, Knellwolf Christina, Sulz Michael, Semadeni Gian-Marco
Abbvie M 14-347
01.03.2015A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease
Klinische Forschung - 01.03.2015 - 01.12.2017
Abgeschlossen
Projektleitung: Borovicka Jan
Mitarbeiter/innen: Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael
Abbvie M14-033
01.03.2015A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis This Phase 3 study design includes a Screening...
Klinische Forschung - 01.03.2015 - 01.02.2018
Automatisch geschlossen
Projektleitung: Borovicka Jan
Mitarbeiter/innen: Dora Barbara, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael
ALERT
28.02.2015VAlidation of an 8-‐item-‐questionnaire predictive for a positive CaLprotectin tEst and Real-‐life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease
Klinische Forschung - 28.02.2015 - 30.01.2017
Abgeschlossen
Projektleitung: Borovicka Jan
Mitarbeiter/innen: Dora Barbara, Sulz Michael
AbbVie M14-115
01.02.2015A Multicenter, Randomisierte, Double-Blind Study to Evaluate the Efficacyand Safety of Two Adalimumab Induction Regimens in Subjects with Moderately to Severely Active Crohns Disease and Evidence of Mucosal Ulceration
Klinische Forschung - 01.02.2015 - 15.02.2018
Automatisch geschlossen
Mitarbeiter/innen: Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael, Dora Barbara
GA28950/Hickory
01.01.2015PHASE III, BLINDED, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE REFRACTORY TO OR INTOLERANT OF TNF INHIBITORS
Klinische Forschung - 01.01.2015 - 31.12.2017
Automatisch geschlossen
Projektleitung: Borovicka Jan
Mitarbeiter/innen: Dora Barbara, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael